Your browser doesn't support javascript.
Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2.
Roxhed, Niclas; Bendes, Annika; Dale, Matilda; Mattsson, Cecilia; Hanke, Leo; Dodig-Crnkovic, Tea; Christian, Murray; Meineke, Birthe; Elsässer, Simon; Andréll, Juni; Havervall, Sebastian; Thålin, Charlotte; Eklund, Carina; Dillner, Joakim; Beck, Olof; Thomas, Cecilia E; McInerney, Gerald; Hong, Mun-Gwan; Murrell, Ben; Fredolini, Claudia; Schwenk, Jochen M.
  • Roxhed N; Micro and Nanosystems, School of Electrical Engineering and Computer Science, KTH Royal Institute of Technology, Stockholm, Sweden. roxhed@kth.se.
  • Bendes A; MedTechLabs, BioClinicum, Karolinska University Hospital, Solna, Sweden. roxhed@kth.se.
  • Dale M; Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.
  • Mattsson C; Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.
  • Hanke L; Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.
  • Dodig-Crnkovic T; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden.
  • Christian M; Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.
  • Meineke B; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden.
  • Elsässer S; Science for Life Laboratory, Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Division of Genome Biology, Solna, Sweden.
  • Andréll J; Ming Wai Lau Centre for Reparative Medicine, Stockholm node, Karolinska Institutet, Solna, Sweden.
  • Havervall S; Science for Life Laboratory, Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Division of Genome Biology, Solna, Sweden.
  • Thålin C; Ming Wai Lau Centre for Reparative Medicine, Stockholm node, Karolinska Institutet, Solna, Sweden.
  • Eklund C; Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, Solna, Sweden.
  • Dillner J; Division of Internal Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Danderyd, Sweden.
  • Beck O; Division of Internal Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Danderyd, Sweden.
  • Thomas CE; Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.
  • McInerney G; Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.
  • Hong MG; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Murrell B; Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.
  • Fredolini C; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden.
  • Schwenk JM; Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.
Nat Commun ; 12(1): 3695, 2021 06 17.
Article in English | MEDLINE | ID: covidwho-1275914
ABSTRACT
Serological testing is essential to curb the consequences of the COVID-19 pandemic. However, most assays are still limited to single analytes and samples collected within healthcare. Thus, we establish a multianalyte and multiplexed approach to reliably profile IgG and IgM levels against several versions of SARS-CoV-2 proteins (S, RBD, N) in home-sampled dried blood spots (DBS). We analyse DBS collected during spring of 2020 from 878 random and undiagnosed individuals from the population in Stockholm, Sweden, and use classification approaches to estimate an accumulated seroprevalence of 12.5% (95% CI 10.3%-14.7%). This includes 5.4% of the samples being IgG+IgM+ against several SARS-CoV-2 proteins, as well as 2.1% being IgG-IgM+ and 5.0% being IgG+IgM- for the virus' S protein. Subjects classified as IgG+ for several SARS-CoV-2 proteins report influenza-like symptoms more frequently than those being IgG+ for only the S protein (OR = 6.1; p < 0.001). Among all seropositive cases, 30% are asymptomatic. Our strategy enables an accurate individual-level and multiplexed assessment of antibodies in home-sampled blood, assisting our understanding about the undiagnosed seroprevalence and diversity of the immune response against the coronavirus.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Specimen Collection / Immunity, Humoral / COVID-19 Serological Testing / COVID-19 Type of study: Observational study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-23893-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Specimen Collection / Immunity, Humoral / COVID-19 Serological Testing / COVID-19 Type of study: Observational study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-23893-4